March #194 : Early Treatment Is Likely Heart Healthy - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Empowering Entrepreneurs

Building Better Barriers

From the Editor

Justify My Love


Letters-March 2014


Southern Star

POZ Planet

Renewed Hope For Organ Transplants

Stigma Index Launches in United States

Say What? Greek Edition

POZ Stories: Blane Oborny

About That $615,000 Banksy?

R.I.P. Nelson Mandela

Fight Club

Wonder Women

Get Real: Focus on Female HIV Prevention


Tables Turned

Care and Treatment

HIV, Not ARVs, Linked to Hardened Arteries

Early Treatment Is Likely Heart Healthy

New Care Guidelines: Focus Beyond HIV

Vaginal Ring Prevents HIV and Pregnancy

A Ballooning Reservoir

Research Notes

Prevention: Breast Milk Protein May Protect Babies

Treatment: Long-Acting ARVs for Low Adherers

Cure: Baby in Remission 18 Months Off ARVs

Concerns: Tests Miss Milder Mental Impairment

POZ Heroes

Beyond the Boundary

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

March 2014

Early Treatment Is Likely Heart Healthy

by Benjamin Ryan

Two new studies showing that maintaining a high CD4 count may lower the risk of cardiovascular disease and death among people with HIV have added yet more voices to the chorus supporting early treatment of the virus. One study found that the risk of a heart attack is linked to a history of a depleted immune system, especially if CD4s have ever dipped below 200. The other found that, after being hospitalized for acute coronary syndrome (ACS, an umbrella term for conditions in which blood flow to the heart is blocked), people with HIV have a greater risk of dying than those without—but not if they have high CD4s.

For the first study, the researchers compared 22,000 HIV-positive people with 230,000 HIV-negative controls who received care from Kaiser Permanente California between 1996 and 2009. After controlling for various factors, they found that the virus was linked to a 44 percent increase in the likelihood of heart attack between the HIV-positive group and the controls. This risk spiked to about 75 percent higher for those whose CD4s had ever dropped below 200. But as for members of the HIV-positive cohort who had always maintained a CD4 count of 500 or above, their risk of heart attack was no different than if they did not have HIV.

“That’s pretty striking to me,” the study’s lead researcher, Michael J. Silverberg, PhD, MPH, a research scientist at Kaiser Permanente Northern California in Oakland, says of the finding that high CD4s can wipe out the excess risk.

In the second study, the scientists analyzed records of people hospitalized for the first time with ACS at Kaiser Permanente Northern California between 1996 and 2010. The study group included 226 people with HIV and 86,000 who were HIV negative. On the whole, those with HIV had more than twice the risk of death a year after the hospitalization as compared with the group without the virus, and a 2.5-fold greater risk three years down the line.

Those HIV-positive people who had CD4s between 200 and 499 were 2.5-times more likely to die after three years than those in the HIV-negative group. This elevated risk of death increased to 5.6-times greater for the HIV-positive people with less than 200 CD4 cells. However, if those in the HIV-positive group had more than 500 CD4s, their risk of death was essentially the same as if they were HIV negative.

People with HIV who were not on ARVs had the greatest overall risk of death: 3.4-times greater than that of the HIV-negative group.

Silverberg says, “These types of studies are important because they are our first signals that starting therapy [will help fight not only] HIV, but also other things that are now known to be related to HIV, like cardiovascular disease.”

Search: cardiovascular disease, death rate, CD4 count, treatment

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.